Exact Sciences ROE - Return on Equity 2010-2025 | EXAS

Exact Sciences return on equity for the quarter ending March 31, 2025 was -36.42.

  • Exact Sciences average return on equity for 2024 was -13.63, a 17.2% increase from 2023.
  • Exact Sciences average return on equity for 2023 was -11.63, a 45.81% increase from 2022.
  • Exact Sciences average return on equity for 2022 was -21.46, a 11.07% decline from 2021.

Roe - return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.

Exact Sciences ROE - Return on Equity 2010-2025 | EXAS

  • Exact Sciences average return on equity for 2024 was -13.63, a 17.2% increase from 2023.
  • Exact Sciences average return on equity for 2023 was -11.63, a 45.81% increase from 2022.
  • Exact Sciences average return on equity for 2022 was -21.46, a 11.07% decline from 2021.

Roe - return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$220.6B
Amgen (AMGN)$158.8B
Gilead Sciences (GILD)$136.4B
Vertex Pharmaceuticals (VRTX)$120.4B
Bristol Myers Squibb (BMY)$95.4B
GSK (GSK)$78.4B
CSL (CSLLY)$76.6B
Regeneron Pharmaceuticals (REGN)$61.3B
Alnylam Pharmaceuticals (ALNY)$41.1B
Argenex SE (ARGX)$34.2B
BioNTech SE (BNTX)$27.1B
Royalty Pharma (RPRX)$20.2B
Biogen (BIIB)$19.7B
Insmed (INSM)$18.6B
Illumina (ILMN)$15.7B
Genmab (GNMSF)$14.2B
Genmab (GMAB)$13.7B
Incyte (INCY)$13.3B
Moderna (MRNA)$13B
Exelixis (EXEL)$12.2B
BioMarin Pharmaceutical (BMRN)$11.1B
QIAGEN (QGEN)$10.7B
Ascendis Pharma (ASND)$10.7B
Swedish Orphan Biovitrum (BIOVF)$10.4B
Verona Pharma American Depositary Share (VRNA)$8.9B
Bio-Techne Corp (TECH)$8.5B
Blueprint Medicines (BPMC)$8.4B
Roivant Sciences (ROIV)$7.7B
Repligen (RGEN)$7.3B
Legend Biotech (LEGN)$7.2B